Senna Side Effects
At typical over-the-counter doses (8.6–17.2 mg daily), senna's most common side effects are abdominal pain, cramping, and diarrhea, which are generally mild and dose-dependent, with no severe adverse events reported in clinical trials. 1
Common Adverse Effects at Standard Doses
The 2023 AGA-ACG guidelines provide the most comprehensive safety data on senna 1:
- Abdominal pain and cramping – The primary limiting side effects, particularly at higher doses
- Diarrhea – Occurs when dosing exceeds individual tolerance
- No severe treatment-related adverse events were documented in the pivotal RCT by Moshita et al.
Critical Dosing Context
The single published RCT used 1 g daily (approximately 100+ mg sennosides), which is significantly higher than typical OTC doses of 8.6–17.2 mg daily 1. Notably, 83% of trial participants reduced their dose during the study, suggesting dose-related tolerability issues even though specific adverse event rates were not reported 1.
Rare but Serious Side Effects
Perineal Blistering and Contact Burns
In diapered children or incontinent patients, prolonged stool-to-skin contact after senna use can cause:
- Sharply demarcated erythema
- Painful blisters and burns in the perineal area
- Risk increases with higher doses (>60 mg/day in pediatric studies) 2
- Occurs in approximately 2.2% of pediatric patients on chronic therapy 2
- Can mimic abusive injury and lead to misdiagnosis 3
Prevention: Frequent diaper changes and prompt cleaning after bowel movements 2, 3
Ischemic Bowel Disease (Elderly Patients)
A case report documents severe ischemic bowel disease in an 87-year-old patient following senna use 4. While rare, this highlights potential vascular risks in elderly patients with compromised intestinal perfusion.
Immune System Disorders
Recent FAERS database analysis (2004-2024) identified immune system disorders as the most frequently reported system organ class associated with senna 5. Risk factors include:
- Advanced age
- Female sex
- Concomitant medications (ascorbic acid, tofacitinib citrate)
- Median onset: 4 days after starting treatment 5
Long-Term Safety Considerations
What We Know
- No evidence of tolerance development despite common clinical concerns 2, 6
- No structural or functional damage to enteric nerves or intestinal smooth muscle with chronic use 6
- No carcinogenic risk in rats even after 2 years at doses up to 300 mg/kg/day 6
- No convincing genotoxic risk for patients taking senna extracts or sennosides 6
What Remains Uncertain
The guidelines explicitly state: "There are no long-term safety studies with senna in humans" 1. This represents a significant knowledge gap given widespread chronic use.
Pseudomelanosis Coli
Chronic senna use causes benign pigmentation of the colonic mucosa (pseudomelanosis coli). While one older study suggested possible association with increased colorectal cancer risk 7, subsequent evidence found no convincing link between chronic senna use and gastrointestinal tumors 6.
Special Populations
Pregnancy
Sennosides are not recommended in pregnant women because chemically similar substances have shown weak genotoxic effects in animal studies, though this evidence remains controversial 1.
Drug Interactions
Antibiotic use may decrease senna efficacy because colonic bacteria are required to metabolize sennosides into active metabolites (rheinanthrone and rhein) 1.
Clinical Pitfalls to Avoid
Starting at high doses: Begin with 8.6–17.2 mg daily and titrate based on response, not the 1 g dose used in trials 1
Ignoring perineal symptoms in children: Always inquire about senna use when perineal burns are observed in pre-continent children 2, 3
Overlooking elderly vascular risk: Exercise caution in elderly patients with known vascular disease 4
Assuming tolerance will develop: No evidence supports this common clinical belief 2, 6
Indefinite use without monitoring: While longer-term use is "probably appropriate," the lack of long-term human safety data warrants periodic reassessment 1
Contraindications (FDA Label)
Per FDA labeling 8:
- Ileus or intestinal obstruction
- Severe dehydration
- Acute inflammatory bowel conditions
- Children under 2 years (consult physician)